Home › Funds › Stonepine Capital Management, LLC › IKT

Stonepine Capital Management, LLC position in IKT

INHIBIKASE THERAPEUTICS INC · Health Care

Stonepine Capital Management, LLC reported holding 647,285 shares of IKT (INHIBIKASE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.3M, representing 1.02% of its reported portfolio and ranking #25 among its reported holdings. Stonepine Capital Management, LLC has disclosed IKT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)647.28K sh
Reported value held$1.33M
Portfolio Weight1.02%
First reportedQ4 2024
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Stonepine Capital Management, LLC's IKT position evolved

Stonepine Capital Management, LLC first disclosed a stake in IKT in Q4 2024 at 1,132,388 shares (US$3.7M). The position peaked in Q4 2025 at 2,348,147 shares, worth US$4.8M. Across 8 filings, Stonepine Capital Management, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 647,285 shares valued at US$1.3M — an increase of 251,106 shares quarter over quarter.. Notable position changes include a 219% increase in Q4 2025 (shares fell 18% over the following quarter), a 59% trim in Q1 2026 (shares rose 21% over the following quarter), a 63% increase in Q3 2026 (shares fell 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 1.13M $3.68M New
Q1 2025 914.97K $2.00M Reduce
Q2 2025 733.79K $1.43M Reduce
Q3 2025 735.02K $1.19M Hold
Q4 2025 2.35M $4.81M Add
Q1 2026 957.20K $1.61M Reduce
Q2 2026 396.18K $804.24K Reduce
Q3 2026 647.28K $1.33M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IKT and 13F data

IKT (INHIBIKASE THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in IKT — the largest reported positions include Sands Capital Alternatives, LLC (US$26.8M), Soleus Capital Management, L.P. (US$22.1M), Trails Edge Capital Partners, LP (US$18.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IKT

All IKT fund holders →

FAQ

How long has Stonepine Capital Management, LLC held IKT?

Stonepine Capital Management, LLC has disclosed IKT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Stonepine Capital Management, LLC's current position in IKT?

As of Q3 2026, Stonepine Capital Management, LLC holds 647.28K shares of IKT (INHIBIKASE THERAPEUTICS INC), valued at $1.33M, representing 1.02% of its reported portfolio and ranking #25.

Has Stonepine Capital Management, LLC been buying or selling IKT?

In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC increased its position in IKT. The position peaked in Q4 2025 at 2.35M shares.

Which other funds hold IKT?

Other major institutional holders of IKT include Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Trails Edge Capital Partners, LP, among 66 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.